抗癌新药dFdC及其放射增敏效应
-
摘要: dFdC是脱氧胞苷的一种类似物,具有全新的药代动力学和药效学特点。它在离体试验、整体试验和临床上都显示出较理想的抗肿瘤活性。目前,dFdC已在许多国家被批准用于治疗非小细胞肺癌和胰腺癌,并正在进行乳腺癌、膀胱癌、小细胞肺癌等恶性肿瘤的各期临床研究。dFdC高效低毒的特点非常适于与其它化疗药物或放疗联合应用。dFdC具有放射增敏效应,其程度受细胞种类、给药剂量和照射时间等影响。dFdC的放射增敏机制尚不十分清楚,可能与胞内dATP水平下降、细胞周期变化等因素有关。
-
[1] Peters G Jet al. Semin Oncol, 1995; 22 (4,Suppl 11):1~2 [2] Shwach DS et al. Proc Am Assoc Cancer Res,1994; 35:425 [3] Gruber J et al. Stem Cells, 1996; 14:351~362 [4] Plunkett W et al. Semin Oncol, 1995; 22(4,Suppl 11):3~10 [5] Von Hoff DD et al. Invest New Drugs, 1996;14:265~270 [6] Burris HAⅢ et al. J Clin Oncol, 1997; 15:2403~2413 [7] Carmichael J. Br J Cancer, 1998; 78(Suppl 3):21~25 [8] Von Hoff DD et al. Br J Cancer, 1998; 78(Suppl 3):9~13 [9] Steward WP. Br J Cancer, 1998; 78(Suppl 3):15~19 [10] Cardenal F et al. Proc Am Soc Clin Oncol,1997; 16:458a [11] Luftner D et al. J Cancer Res Clin Oncol, 1998;124:527~531 [12] Shewach DS et al. Cancer Res, 1994; 54 (12):3218~3223 [13] Lawrence TS et al. Int J Radiat Oncol Biol Phys, 1996; 34:867~872 [14] Jaschko M A et al. Radiat Oncol Invest, 1997;5(2):62~71 [15] Lawrence TS et al. Clin Cancer Res, 1997; 3(5):777~782 [16] Gregoire V et al. Br J Cancer, 1997; 76(10):1315~1321 [17] Fujii T et al. Proceedings of the 45th Annual Meeting of the Radiation Research Society, Providcnce. RI, 1997; 229 [18] Goor C et al. Ann Oncol, 1997; 7:101 [19] Ostruszka LJ et al. Proc Am Assoc Cancer Res, 1997; 38:683 [20] Shewach DS et al. Semin Oncol, 1995; 22 (4,Suppl 11):68~71 [21] Lawrence TS et al. Semin Oncol, 1997; 24 (2,Suppl 7):24~28 [22] Shewach DS et al. Invest New Drug, 1996; 14(3):257~263 [23] Huang NJ et al. Proc Am Assoc Cancer Res,1995; 36:612 [24] Gregoire V et al. Int J Radiat Biol, 1998; 73(5):511~520
点击查看大图
计量
- 文章访问数: 1203
- HTML全文浏览量: 159
- PDF下载量: 2